159 related articles for article (PubMed ID: 15141426)
21. Serotonergic modulation of bladder afferent pathways.
Burgard EC; Fraser MO; Thor KB
Urology; 2003 Oct; 62(4 Suppl 1):10-5. PubMed ID: 14550832
[TBL] [Abstract][Full Text] [Related]
22. The effect of duloxetine on urethral sphincter morphology.
Duckett J; Patil A; Aggarwal I
Ultrasound Obstet Gynecol; 2008 Feb; 31(2):206-9. PubMed ID: 18254135
[TBL] [Abstract][Full Text] [Related]
23. Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Fischer F; Vonderlin N; Seyler C; Zitron E; Schernus B; Katus H; Scholz E
Naunyn Schmiedebergs Arch Pharmacol; 2013 Sep; 386(9):795-804. PubMed ID: 23666493
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor.
Engleman EA; Perry KW; Mayle DA; Wong DT
Neuropsychopharmacology; 1995 Jul; 12(4):287-95. PubMed ID: 7576005
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems.
Rueter LE; De Montigny C; Blier P
J Pharmacol Exp Ther; 1998 May; 285(2):404-12. PubMed ID: 9580577
[TBL] [Abstract][Full Text] [Related]
27. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain.
Kasamo K; Blier P; De Montigny C
J Pharmacol Exp Ther; 1996 Apr; 277(1):278-86. PubMed ID: 8613930
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine: a dual reuptake inhibitor.
Dugan SE; Fuller MA
Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model.
Angulo J; Cuevas P; Cuevas B; Gupta S; Sáenz de Tejada I
J Pharmacol Exp Ther; 2004 Jul; 310(1):141-9. PubMed ID: 15034084
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine: a review of its pharmacology and use in chronic pain management.
Bellingham GA; Peng PW
Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents.
Jones CK; Peters SC; Shannon HE
J Pharmacol Exp Ther; 2005 Feb; 312(2):726-32. PubMed ID: 15494550
[TBL] [Abstract][Full Text] [Related]
32. Duloxetine: a new approach for treating stress urinary incontinence.
Moore K
Int J Gynaecol Obstet; 2004 Jul; 86 Suppl 1():S53-62. PubMed ID: 15302567
[TBL] [Abstract][Full Text] [Related]
33. Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits.
Ossewaarde L; Verkes RJ; Hermans EJ; Kooijman SC; Urner M; Tendolkar I; van Wingen GA; Fernández G
Biol Psychiatry; 2011 Sep; 70(6):568-74. PubMed ID: 21601833
[TBL] [Abstract][Full Text] [Related]
34. Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Rastogi R; Swarm RA; Patel TA
Anesthesiology; 2011 Dec; 115(6):1291-8. PubMed ID: 22037635
[No Abstract] [Full Text] [Related]
35. Comparative effects of clomipramine and duloxetine on detrusor and striated sphincter function in male and female rabbits.
Pérez Martínez FC; Vela Navarrete R; Castilla Reparaz C
Arch Esp Urol; 2006 Oct; 59(8):839-48. PubMed ID: 17153510
[TBL] [Abstract][Full Text] [Related]
36. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
37. Role of serotonin and noradrenaline in stress urinary incontinence.
Michel MC; Peters SL
BJU Int; 2004 Jul; 94 Suppl 1():23-30. PubMed ID: 15139860
[No Abstract] [Full Text] [Related]
38. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents.
Jones CK; Peters SC; Shannon HE
Eur J Pain; 2007 Feb; 11(2):208-15. PubMed ID: 16542861
[TBL] [Abstract][Full Text] [Related]
39. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
Hua TC; Pan A; Chan C; Poo YK; Skinner MH; Knadler MP; Gonzales CR; Wise SD
Br J Clin Pharmacol; 2004 May; 57(5):652-6. PubMed ID: 15089819
[TBL] [Abstract][Full Text] [Related]
40. Stability of the acetic acid-induced bladder irritation model in alpha chloralose-anesthetized female cats.
Kullmann FA; Wells GI; Langdale CL; Zheng J; Thor KB
PLoS One; 2013; 8(9):e73771. PubMed ID: 24040064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
